Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS

Chuan Xing; Chunzhu Li; Bing He

Disclosures

J Clin Endocrinol Metab. 2020;105(9) 

In This Article

Conclusion

For overweight women with PCOS, both metformin combined with GLP-1 receptor agonists and metformin combined with TZDs appear superior to monotherapy in improving hyperandrogenemia. Metformin combined with TZDs could be particularly effective in promoting the recovery of menstruation. Metformin combined with GLP-1 receptor agonists has additional advantage in improving fasting glucose when compared with GLP-1 receptor agonists alone. TZDs is inferior to metformin in decreasing BMI. Overall, the available evidence is not of high quality, therefore, large-scale clinical trials are urgently needed to study different interventions with insulin-sensitive drugs in order to further guide the clinical treatment of women with PCOS.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....